DNA Vaccine Protects Against Alzheimer’s Toxic Proteins

Summary: Researchers report a new DNA vaccine prompts an immune response to proteins associated with Alzheimer’s disease.

Source: UT Southwestern Medical Center.

A new DNA vaccine when delivered to the skin prompts an immune response that produces antibodies to protect against toxic proteins associated with Alzheimer’s disease – without triggering severe brain swelling that earlier antibody treatments caused in some patients.

Two studies from the Peter O’Donnell Jr. Brain Institute demonstrate in animals how a vaccine containing DNA of the toxic beta-amyloid protein elicits a different immune response that may be safe for humans.

The vaccine, which will likely be tested further by the U.S. Food and Drug Administration, is on a shortlist of promising antibody treatments that may eventually help settle a high-stakes debate of whether amyloid is a vital target for preventing or curing Alzheimer’s.

“If you look at the hard reality, the odds are against us because so many therapies have failed through the years. But this has potential,” said Dr. Roger Rosenberg, co-author of the studies and Director of the Alzheimer’s Disease Center at UT Southwestern Medical Center.

Dr. Rosenberg notes that earlier research established that antibodies significantly reduce amyloid buildup in the brain, but he needed to find a safe way to introduce these into the body. A vaccine developed elsewhere showed promise in the early 2000s, but when tested in humans it caused brain swelling in some patients.

Dr. Rosenberg’s idea was to start with DNA coding for amyloid and inject it into the skin rather than the muscle. The injected skin cells make the amyloid protein, and the body responds by producing new antibodies that inhibit the buildup of amyloid, which some scientists blame for destroying neurons.

Although the DNA vaccine has not yet been tested in humans, it produces a different kind of immune response in the tested animals that significantly lessens the chance of an adverse response in the brain, according to the studies published in the Journal of Alzheimer’s Disease and Alzheimer’s Research & Therapy.

The research is notable because it shows a DNA vaccine can be effective and safe in two large mammals. Most other vaccines only produced an immune response in mice but not large mammals.

“We believe this kind of immune response has a high probability of being safe in humans and also being effective to make high levels of antibody,” said Dr. Rosenberg, Professor of Physiology, Neurology and Neurotherapeutics.

Alzheimer’s disease is characterized by progressive deterioration of the brain as neurons are destroyed. More than 5 million Americans have the fatal disease, with the number expected to nearly triple by 2050, according to the Centers for Disease Control and Prevention.

No known cure exists, though an array of antibody and other treatments are being researched to target amyloid plaques. One strategy involves preforming the antibodies in the laboratory and inserting them into the body – a technique that is still being tested for clinical benefits.

Dr. Rosenberg said there would be distinct advantages to allowing the body to produce its own antibodies through active immunization, if it can be done safely. Among them, the vaccine would be more accessible and less expensive. It also produces a wider variety of antibody types than the preformed antibodies, he said.

“All the vaccines we received as kids and adults have been active vaccinations; we made the antibodies in the body,” Dr. Rosenberg said. “It’s safer, more effective, and it’s sustained longer.”

Dr. Rosenberg’s research is the latest contribution to decades of study across the globe focusing on clearing amyloid plaques in hopes of curing or slowing the progression of Alzheimer’s. A lack of results over the years has prompted some scientists to question whether they are properly targeting the disease.

A British study from 2008 showed that removing amyloid after it accumulates in the brain does not improve brain cognition. The findings highlight a couple of lingering questions that have crucial implications for the future of Alzheimer’s research: Is amyloid merely a symptom, not the cause of the disease? And if there is causation, can earlier treatments make a difference?

Image shows antibodies.
UT Southwestern researchers have developed a DNA vaccine that helps the body protect against toxic proteins associated with Alzheimer’s disease. These images show amyloid plaque in the mouse brain using plasma containing anti-amyloid antibody from large mammals immunized with the vaccine. NeuroscienceNews.com image is credited to UT Southwestern.

Dr. Rosenberg acknowledges that preventing amyloid buildup by itself may not be an adequate treatment for Alzheimer’s, but it could be a major part of the solution. He and other researchers at UT Southwestern are also studying the potential benefits of preventing and removing tangles of toxic tau proteins from the brain, another hallmark of the disease.

“Some in the scientific community believe the reason amyloid therapies have failed so far is because too little of the therapy was given, and too late,” Dr. Rosenberg said. “The jury is still out.”

Dr. Rosenberg’s latest studies show the potential of a DNA vaccine to prevent the buildup of amyloid in otherwise healthy people. The vaccine was administered to healthy animals, inducing an anti-inflammatory immune response of up to 40 times more anti-amyloid antibodies than an earlier vaccine Dr. Rosenberg tested a decade ago.

Dr. Rosenberg expects the FDA will want further tests of the vaccine in its own labs before planning a potential clinical trial on people. If proven effective, the vaccine could be given to people who are at risk of developing Alzheimer’s but have not yet started forming amyloid plaques.

Dr. Rosenberg keeps his expectations in check, noting the billions of dollars and multitude of studies that have so far yielded little advancement in treating Alzheimer’s disease.

“Finding answers to this disease will knock you down fast,” said Dr. Rosenberg, who has worked at UT Southwestern for 44 years and holds the Abe (Brunky), Morris and William Zale Distinguished Chair in Neurology. “I’ve made a commitment to this place and to this research. I’m trying, and I’ll keep going.”

About this neuroscience research article

Study collaborators include co-author Dr. Doris Lambracht-Washington, Instructor of Neurology and Neurotherapeutics, and Min Fu, Senior Research Associate. The Texas Biomedical Research Institute in San Antonio and Animal Resource Center in Dallas helped in the studies.

Funding: The research was funded by the National Institute on Aging, the Zale Foundation, the McCune Foundation, the Rudman Foundation, the Alliance of Women for Alzheimer’s Research and Education, Presbyterian Village North Foundation; and Freiberger, Losinger, and Denker Family Funds.

Source: James Beltran – UT Southwestern Medical Center
Image Source: NeuroscienceNews.com image is credited to UT Southwestern.
Original Research: Full open access research for “Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer” by Lambracht-Washington, Doris; Fu, Min; Wight-Carter, Mary; Riegel, Matthew; and Rosenberg, Roger N. in Journal of Alzheimer’s Disease. Published online March 4 2017 doi:10.3233/JAD-160947

Full open access research for “Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer” by Doris Lambracht-Washington, Min Fu, Pat Frost and Roger N. Rosenberg in Alzheimer’s Research and Therapy. Published online April 26 2017 doi:10.1186/s13195-017-0257-7

Cite This NeuroscienceNews.com Article

[cbtabs][cbtab title=”MLA”]UT Southwestern Medical Center “DNA Vaccine Protects Against Alzheimer’s Toxic Proteins.” NeuroscienceNews. NeuroscienceNews, 23 May 2017.
<https://neurosciencenews.com/alzheimers-dna-vaccine-6752/>.[/cbtab][cbtab title=”APA”]UT Southwestern Medical Center (2017, May 23). DNA Vaccine Protects Against Alzheimer’s Toxic Proteins. NeuroscienceNew. Retrieved May 23, 2017 from https://neurosciencenews.com/alzheimers-dna-vaccine-6752/[/cbtab][cbtab title=”Chicago”]UT Southwestern Medical Center “DNA Vaccine Protects Against Alzheimer’s Toxic Proteins.” https://neurosciencenews.com/alzheimers-dna-vaccine-6752/ (accessed May 23, 2017).[/cbtab][/cbtabs]


Abstract

Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer

A pathological hallmark of Alzheimer’s disease (AD) are amyloid plaques in the brain consisting of aggregated amyloid-β 42 peptide (Aβ42) derived from cellular amyloid-β protein precursor (AβPP). Based on successful experiments in mouse AD models, active immunization with Aβ42 peptide and passive immunizations with anti-Aβ42 antibodies were started in clinical trials. Active Aβ42 peptide immunization in humans had led to an inflammatory autoimmune response, and the trial was stopped. Passive immunizations had shown some effects in slowing AD pathology. Active DNA Aβ42 immunizations administered with the gene gun into the skin elicits a different immune response and is non-inflammatory. While in rodents, good responses had been found for this type of immunization, positive results in larger mammals are missing. We present here results from sixteen New Zealand White Rabbits, which underwent intradermal DNA Aβ42 immunization via gene gun. The humoral immune response was analyzed from blood throughout the study, and cellular immune responses were determined from spleens at the end of the study. A good anti-Aβ antibody response was found in the rabbit model. The T cell response after re-stimulation in cell culture showed no IFNγ producing cells when ELISPOT assays were analyzed from PBMC, but low numbers of IFNγ and IL-17 producing cells were found in ELISPOTS from spleens (both 5 immunizations). Brains from immunized rabbits showed no signs of encephalitis. Based on these results, DNA Aβ42 immunization is highly likely to be safe and effective to test in a possible clinical AD prevention trial in patients.

“Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer” by Lambracht-Washington, Doris; Fu, Min; Wight-Carter, Mary; Riegel, Matthew; and Rosenberg, Roger N. in Journal of Alzheimer’s Disease. Published online March 4 2017 doi:10.3233/JAD-160947


Abstract

Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer

Background
Aggregated amyloid-β peptide 1–42 (Aβ42), derived from the cellular amyloid precursor protein, is one of the pathological hallmarks of Alzheimer’s disease (AD). Although active immunization against Aβ42 peptide was successful in AD mouse models and led to removal of plaques and improved memory, a similar clinical trial in humans (Aβ42 peptide immunization with QS-21 adjuvant) was stopped in phase II, when 6% of the treated patients developed encephalitis. Currently ongoing passive immunizations with the injection of preformed monoclonal antibodies against different epitopes within the Aβ1–42 peptide, which do not lead to activation of the immune system, have shown some effects in slowing AD pathology. Active DNA Aβ42 immunizations administered with the gene gun into the skin are noninflammatory because they activate a different T-cell population (Th2) with different cytokine responses eliciting a different humoral immune response. We present our findings in rhesus macaques that underwent the DNA Aβ42 immunization via gene gun delivery into the skin.

Methods
Six rhesus monkeys received two different doses of a DNA Aβ42 trimer vaccine. The humoral immune response was analyzed from blood throughout the study, and cellular immune responses were determined in peripheral blood mononuclear cells (PBMCs) after three and six immunizations.

Results
DNA Aβ42 trimer immunization led to high titer antibody responses in the nonhuman primate (NHP) model. Antibodies generated in the rhesus monkeys following DNA Aβ42 immunization detected amyloid plaques consisting of human Aβ42 peptide in the brain of the triple-transgenic AD mouse model. T-cell responses showed no interferon (IFN)-γ- and interleukin (IL)-17-producing cells from PBMCs in Enzyme-Linked ImmunoSpot assays after three immunization time points. At six immunization time points, IFN-γ- and IL-17-producing cells were found in immunized animals as well as in control animals and were thus considered nonspecific and not due to the immunization regimen. IFN-γ and IL-17 secretion in response to Aβ42 peptide restimulation became undetectable after a 3-month rest period.

Conclusions
Intradermal DNA Aβ42 immunization delivered with the gene gun produces a high antibody response in NHPs and is highly likely to be effective and safe in a clinical AD prevention trial in patients.

“Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer” by Doris Lambracht-Washington, Min Fu, Pat Frost and Roger N. Rosenberg in Alzheimer’s Research and Therapy. Published online April 26 2017 doi:10.1186/s13195-017-0257-7

Feel free to share this Neuroscience News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.